Online ISSN: 3007-0244,
Print ISSN:  2410-4280
Immunotherapy by choosing a personalized treatment based on efficacy, favorable toxicity profile and tolerability consistent with the results of randomized clinical trials (KEYNOTE) is a promising new approach to the treatment of metastatic non-small cell lung cancer. Currently, in the treatment of non-small cell lung cancer, the range of immunotherapeutic drugs has significantly expanded, the use of which makes it possible to achieve tumor control while maintaining the quality of life of patients and reducing or absence of clinical symptoms and immuno-mediated adverse events. One of these drugs is Pembrolizumab (a monoclonal antibody that blocks the interaction between PD–1 and its ligands (PD-L1/PD-L2)), which is used in both second and first-line therapy, provided a high level of PD-L1 expression (≥50%). This paper describes a clinical case of a patient with non-small cell lung cancer, with PD-L1 expression, who received immunotherapy with pembrolizumab. During immunotherapy, the patient's cough and chest pain decreased clinically, the quality of life and the duration of partial regression improved by more than 6 months. There were no immuno-mediated adverse events in the patient during the entire period of treatment and follow-up. The data presented in the article will be useful to oncologists, chemotherapists, oncosurgeons, radiologists, histologists, therapists.
Zhanar S. Tumenbayeva1, Abai K. Makishev2, 1 South Kazakhstan Medical Academy, Shymkent, Republic of Kazakhstan; 2 NCJSC “Astana Medical University”, Astana, Republic of Kazakhstan.
1. Bonomi P. Implications of key trials in advanced non-small cell lung cancer. Cancer, 2010, 116: 1155-64. 2. Brahmer J.R., Rodríguez-Abreu D., Robinson A.G., Hui R. et al. Updated Analysis of KEYNOTE-024: Pembrolizumab Versus Platinum-based Chemotherapy for Advanced NSCLC With PD-L1 TPS ≥50%. Journal of Thoracic Oncology, 2017 Nov, 12(11): 1793-1794. 3. Chae Y.K., Pan A., Davis A.A., Raparia K. et al. Biomarkers for PD-1/PD-L1 Blockade Therapy in Non-Small cell Lung Cancer: Is PD-L1 Expression a Good Marker for Patient Selection? Clin. Lung Cancer, 2016, 17(5): 350-361. 4. Garon E.B., Rizvi N.A., Hui R., et al. Pembrolizumab for the treatment of non-small cell lung cancer. N Engl J Med, 2015, 372: 2018-28. 5. Herbst R. et al. Pembrolizumab versus docetaxel for previously treated, PD-L1-positive, advanced non-small-cell lung cancer (KEYNOTE-010): a randomised controlled trial. Lancet, 2016 Apr 9, 387(10027): 1540-50. doi: 10.1016/S0140-6736(15)01281-7. 6. Leighl N., Hellmann M., Hui R. et al. KEYNOTE-001: 3-year overall survival for patients with advanced NSCLC treated with pembrolizumab. Journal of Clinical Oncology, 2017 May, 35(15_suppl): 9011-9011. doi: 10.1200/JCO.2017.35.15_suppl.9011. 9. Reck M., Rodríguez-Abreu D., Robinson A.G., Hui R., Csőszi T., Fülöp A., et al. Pembrolizumab versus chemotherapy for PD-L1–positive non–small cell lung cancer. N Engl J Med, 2016, 375(19): 1823-33. 10. Sandler A., Gray R., Perry M.C., Brahmer J., Schiller J.H., Dowlati A., et al. Paclitaxel-carboplatin alone or with bevacizumab for non-small cell lung cancer. N Engl J Med, 2006, 355: 2524-50. 11. Scagliotti G., Parikh P., von Pawel J. et al. Phase III study comparing cisplatin plus gemcitabine with cisplatin plus pemetrexed in chemotherapy naïve patients with advanced-stage non-small cell lung cancer. J Clin Oncol, 2008, 26: 3543-51. 12. Shaverdian N., Lisberg A., Bornazyan K. et al. Previous radiotherapy and the clinical activity and toxicity of pembrolizumab in the treatment of non-small cell lung cancer: a secondary analysis of the KEYNOTE-001 phase 1 trial. Lancet Oncol, 2017. Published Online May 24, 2017. doi: 10.1016/S1470-2045(17)30380-7.
Number of Views: 36

Category of articles: Clinical case

Bibliography link

Tumenbayeva Zh.S., Makishev A.K. A clinical case of non-small cell therapy lung cancer with PD-L1 expression // Наука и Здравоохранение. 2024. Т.26 (2). С. 241-245. doi 10.34689/SH.2024.26.2.028

Авторизируйтесь для отправки комментариев